Apadenoson
- Generic Name
- Apadenoson
- Drug Type
- Small Molecule
- Chemical Formula
- C23H30N6O6
- CAS Number
- 250386-15-3
- Unique Ingredient Identifier
- BTS1Y6777M
- Background
Apadenoson is a selective A2a adenosine receptor agonist designed for use as a pharmacologic stress agent in cardiac perfusion imaging studies. It is developed by Bristol-Myers Squibb and is in phase II of clinical trials.
- Indication
Investigated for use/treatment in cardiovascular disorders and inflammatory disorders (unspecified).
Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI
- Conditions
- Coronary Artery Disease
- Interventions
- First Posted Date
- 2011-03-11
- Last Posted Date
- 2012-05-01
- Lead Sponsor
- Forest Laboratories
- Target Recruit Count
- 197
- Registration Number
- NCT01313572
- Locations
- 🇺🇸
Forest Investigative Site 162, New Brunswick, New Jersey, United States
🇺🇸Forest Investigative Site 143, Melbourne, Florida, United States
🇧🇷Forest Investigative Site 308, Belo Horizonte, Brazil
Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI
- Conditions
- Coronary Artery Disease
- Interventions
- First Posted Date
- 2009-10-06
- Last Posted Date
- 2012-05-01
- Lead Sponsor
- Forest Laboratories
- Target Recruit Count
- 863
- Registration Number
- NCT00990327
- Locations
- 🇺🇸
Forest Investigative Site 235, Akron, Ohio, United States
🇺🇸Forest Investigative Site 229, Spartanburg, South Carolina, United States
🇺🇸Forest Investigative Site 227, Chicago, Illinois, United States
A Comparison Study of Apadenoson and Adenosine to Treadmill Exercise Stress.
- Conditions
- Coronary Artery Disease
- First Posted Date
- 2006-09-25
- Last Posted Date
- 2017-02-01
- Lead Sponsor
- Forest Laboratories
- Target Recruit Count
- 1500
- Registration Number
- NCT00380198
- Locations
- 🇺🇸
Local Institution, Madison, Wisconsin, United States
A Phase II Optimization Study of BMS068645 and Sestamibi Planar Imaging
- Conditions
- Ischemic Heart DiseaseCardiovascular Disease
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2017-02-01
- Lead Sponsor
- Forest Laboratories
- Target Recruit Count
- 20
- Registration Number
- NCT00162071
- Locations
- 🇺🇸
Local Institution, New York, New York, United States
A Study to Examine MPI SPECT Imaging With BMS068645 and Adenosine Compared to Coronary Angiography
- Conditions
- Heart DiseaseIschemic Heart Disease
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2017-02-01
- Lead Sponsor
- Forest Laboratories
- Target Recruit Count
- 2000
- Registration Number
- NCT00162084
- Locations
- 🇺🇸
Local Institution, Wausau, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.